ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 116 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,915 | -57.6% | 4,774 | -33.7% | 0.00% | – |
| Q2 2023 | $54,049 | -50.3% | 7,197 | -70.1% | 0.00% | – |
| Q1 2023 | $108,674 | -60.6% | 24,043 | -1.8% | 0.00% | – |
| Q4 2022 | $275,923 | +18.9% | 24,483 | +1.1% | 0.00% | – |
| Q3 2022 | $232,000 | +17.2% | 24,220 | -1.1% | 0.00% | – |
| Q2 2022 | $198,000 | -19.5% | 24,490 | +68.2% | 0.00% | – |
| Q1 2022 | $246,000 | -30.5% | 14,557 | -11.7% | 0.00% | – |
| Q4 2021 | $354,000 | -70.4% | 16,495 | +2.0% | 0.00% | -100.0% |
| Q3 2021 | $1,194,000 | -10.7% | 16,170 | -33.9% | 0.00% | 0.0% |
| Q2 2021 | $1,337,000 | -31.1% | 24,452 | -7.1% | 0.00% | -33.3% |
| Q1 2021 | $1,940,000 | +52.9% | 26,315 | +78.7% | 0.00% | +50.0% |
| Q4 2020 | $1,269,000 | +132.0% | 14,725 | +1.6% | 0.00% | +100.0% |
| Q3 2020 | $547,000 | – | 14,486 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $530,392,000 | 62.60% |
| Logos Global Management LP | 3,156,981 | $172,624,000 | 14.51% |
| Vivo Capital, LLC | 4,220,048 | $230,752,000 | 9.99% |
| Foresite Capital Management V, LLC | 231,200 | $12,642,000 | 4.97% |
| Cormorant Asset Management, LP | 889,454 | $48,635,000 | 1.65% |
| Board of Trustees of The Leland Stanford Junior University | 259,982 | $14,216,000 | 1.33% |
| Redmile Group, LLC | 914,035 | $49,979,000 | 0.74% |
| SPHERA FUNDS MANAGEMENT LTD. | 192,728 | $10,538,000 | 0.71% |
| Financial Advisory Group | 54,041 | $2,955,000 | 0.71% |
| Nan Fung Group Holdings Ltd | 34,950 | $1,911,000 | 0.59% |